Log In
Print
BCIQ
Print
Print this Print this
 

roxadustat (ASP1517, FG-4592)

  Manage Alerts
Collapse Summary General Information
Company FibroGen Inc.
DescriptionSmall molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN)
Molecular Target Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN)
Mechanism of ActionHypoxia-inducible factor prolyl hydroxylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAnemia
Indication DetailsTreat anemia in chronic kidney disease (CKD) patients; Treat anemia in chronic kidney disease (CKD) patients not on dialysis; Treat anemia in chronic kidney disease (CKD) patients not on dialysis and on dialysis; Treat anemia in chronic kidney disease (CKD) patients on dialysis; Treat anemia in patients with end-stage renal disease (ESRD)
Regulatory Designation
Partner Astellas Pharma Inc.; AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$350.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today